Astellas Purchase Of OSI Seen Providing Quick Recovery Following Patent Loss
This article was originally published in PharmAsia News
Executive Summary
By acquiring a U.S. drug maker, Astellas Pharma expects to fill a key gap in its pharmaceutical pipeline at a time it needs to supplant earnings from drugs facing expiring patents